Thomas Powles outlines the DANUBE trial pitting durvalumab, with or without tremelimumab, against chemotherapy in the metastatic urothelial cancer setting (4:37).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany